

Your source for the latest research news

Science News

from research organizations

Taking the STING out of MND

Date: October 7, 2020

Source: Walter and Eliza Hall Institute

Summary: Researchers are working towards a potential treatment to slow the progression of motor neuron disease (MND). The research team have uncovered how inflammation in MND is triggered. Pinpointing the molecules involved in this pathway could be a first step towards a new treatment for MND.

Share: f 🎔 🦻 in 🗹

FULL STORY

Melbourne researchers are working towards a potential treatment to slow the progression of motor neuron disease (MND), offering hope to people with this debilitating and incurable illness.

The research team have uncovered how inflammation in MND is triggered. Pinpointing the molecules involved in this pathway could be a first step towards a new treatment for MND.

They found that by blocking an immune sensor called STING, they could dramatically prevent inflammation from MND patient cells, paving the way for a new class of drugs to be developed for people with neurode-generative disorders, such as MND.

The discovery, published today in *Cell*, was led by Walter and Eliza Hall Institute researchers Associate Professor Seth Masters and Dr Alan Yu, with colleagues from the University of Melbourne and Hudson Institute.

Halting the inflammatory response

MND is an incurable condition in which the nerve cells controlling the muscles that enable us to move, speak, swallow and breathe, fail to work. One in 10,000 Australians will be diagnosed with MND in their life-time and the average life expectancy from diagnosis is just two years.

Most people suffering from MND have an accumulation of a protein called TDP-43 within cells of the central nervous system. This build-up is associated with an inflammatory response that precedes major symptoms of MND.

Institute researchers investigated how the disease-causing inflammation is triggered in MND, said Associate Professor Masters. "This unexpectedly identified that an immune sensor called STING is acti-

vated downstream of TDP-43. Fortuitously, our team had already studied the role of STING in other inflammatory diseases and are now working out how to block it."

The team then used new inhibitors -- drug-like compounds -- to block different components of this inflammatory pathway.

"Using cells from patients with MND that we can turn into motor neurons in a dish, we showed that blocking STING dramatically prevented inflammation and kept the cells alive longer. This is an exciting first step before taking these inhibitors into the clinic for treatment for MND.

Vital first step towards a treatment

Associate Professor Masters said his research had also established activation of STING in people who had passed away due to MND.

"We are now aiming to validate a biomarker of the pathway earlier in the disease progression. Once this neuroinflammatory biomarker is validated, we will better understand which patients will benefit the most from treatments targeting the pathway," he said.

"With this knowledge, there is the potential to develop a treatment for patients with MND.

"Interestingly, our preclinical models suggest that although the anti-inflammatory drugs that inhibit STING did not prevent disease onset, they did slow the degenerative progression of disease."

Hope for people with MND and other neurodegenerative disorders

Associate Professor Masters said this discovery offered hope for people diagnosed with the debilitating condition.

"We are hopeful this research could lead to a treatment for people with established MND, who currently have very few treatment options and a life expectancy post diagnosis of just two to five years," he said.

"While it isn't a cure, we hope it might extend life expectancy and dramatically improve the quality of life for people diagnosed with MND."

Associate Professor Masters said a future treatment might also be effective in slowing the progression of other neurodegenerative disorders.

"We are hoping to develop a new class of drugs that would act as STING inhibitors to stop the progression of neurodegenerative disorders, such as MND, Frontotemporal Dementia and Parkinson's disease."

Story Source:

Materials provided by Walter and Eliza Hall Institute. Note: Content may be edited for style and length.

Journal Reference:

 Chien-Hsiung Yu, Sophia Davidson, Cassandra R. Harapas, James B. Hilton, Michael J. Mlodzianoski, Pawat Laohamonthonkul, Cynthia Louis, Ronnie Ren Jie Low, Jonas Moecking, Dominic De Nardo, Katherine R. Balka, Dale J. Calleja, Fiona Moghaddas, Erya Ni, Catriona A. McLean, Andre L. Samson, Shiraz Tyebji, Christopher J. Tonkin, Christopher R. Bye, Bradley J. Turner, Genevieve Pepin, Michael P. Gantier, Kelly L. Rogers, Kate McArthur, Peter J. Crouch, Seth L. Masters. **TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS**. *Cell*, 2020; DOI: 10.1016/j.cell.2020.09.020

Cite This Page:	MLA	APA	Chicago	
			- 0	

Walter and Eliza Hall Institute. "Taking the STING out of MND." ScienceDaily. ScienceDaily, 7 October 2020. <www.sciencedaily.com/releases/2020/10/201007123101.htm>.

RELATED STORIES

How MND Affects Multiple Brain Networks

July 31, 2019 — Researchers have identified characteristic changes in the patterns of electrical brain wave activity in motor neurone disease (MND). This ground breaking observation will help to develop treatments ...

Decoding the Causes of Motor Neuron Disease: A New Study Shows the Impact of Genetics July 24, 2019 — Researchers have conducted the largest ever study involving 1117 people diagnosed with motor neuron disease to address the question of "nature versus nurture" in the causes of MND. The team found ...

New Discovery in Motor Neuron Disease and Dementia Could Pave the Way to Novel Treatments July 17, 2017 — A new discovery could help slow down the progression of neurodegenerative diseases such as motor neuron disease (MND), dementia and neurological decline associated with ...

Delaying Motor Neuron Loss

Sep. 21, 2016 — A potential treatment to delay motor neuron loss and symptoms has been discovered in the inevitably fatal motor neuron disease (MND). Researchers have reported that triheptanoin, a synthetic ...

FROM AROUND THE WEB

ScienceDaily shares links with sites in the TrendMD network and earns revenue from third-party advertisers, where indicated.

Alzheimer's Disease Including Focal Presentations

Nicolas Villain et al., Seminars in Neurology, 2019

Medicinal Plants and Natural Products as Potential Sources for Antiparkinson Drugs José-Luis Ríos et al., Planta Medica, 2016

6-Hydroxycleroda-3,13-dien-15,16-olide Protects Neuronal Cells from Lipopolysaccharide-Induced Neurotoxicity through the Inhibition of Microglia-Mediated Inflammation Yu-Tzu Shih et al., Planta Medica, 2009

Molecular Classifier Developed to Detect Cases of Pediatric Irritable Bowel Syndrome John Gilmore, 360Dx, 2019

Combined Inhibition of PDE4 and PI3Kδ Modulates the Inflammatory Component Involved in the Progression of Chronic Obstructive Pulmonary Disease

S. S. Dinavahi et al., Drug Research, 2013

Mechanisms of Action of Phytochemicals from Medicinal Herbs in the Treatment of Alzheimer's Disease

Mi Hye Kim et al., Planta Medica, 2014

German Genomic Service Provider Details Implementation of Multiplicom's NIPT 360Dx, 2017

Biocartis Lands €2.5M Grant From Flemish Government to Expand Manufacturing Capacity staff reporter, 360Dx, 2016

Powered by TREND MD

Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

- Email Newsletters
- RSS Feeds

Follow Us

Keep up to date with the latest news from ScienceDaily via social networks:

- f Facebook
- Twitter
- in LinkedIn

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

- Leave Feedback
- Contact Us

About This Site | Staff | Reviews | Contribute | Advertise | Privacy Policy | Editorial Policy | Terms of Use

Copyright 2020 ScienceDaily or by other parties, where indicated. All rights controlled by their respective owners.

Content on this website is for information only. It is not intended to provide medical or other professional advice. Views expressed here do not necessarily reflect those of ScienceDaily, its staff, its contributors, or its partners. Financial support for ScienceDaily comes from advertisements and referral programs, where indicated.

- GDPR: Privacy Settings -